相关实验视频

Updated: Jun 14, 2025

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

选择与HLA不匹配的非相关和偶同的捐赠者:捐赠者的年龄考虑

Rohtesh S Mehta¹, Gabrielle Schmidt², Kirsten Williams³

¹Stem Cell Transplantation and Cellular Therapies, University of Texas, MD Anderson Cancer Center, Houston, Texas.

Transplantation and cellular therapy

|May 26, 2025

概括

较年轻的造血细胞移植捐赠者 (<30岁) 改善了结果,包括无GVHD生存率,无论捐赠者类型 (haploidentical或无关). 优先考虑年轻的捐赠者可以提高患者的生存率,并减少移植并发症.

科学领域:

血液学血液学血液学
移植免疫学移植免疫学
在瘤学瘤学.

背景情况:

哈普洛同一性捐赠者和HLA不匹配的非相关捐赠者 (MMUDs) 越来越多地用于血液细胞移植 (HCT).
移植后循环胺 (PTCy) 是一种常见的移植对宿主疾病 (GVHD) 预防.
需要进一步澄清以PTCy为基础的GVHD预防治疗对HCT结果的捐赠者年龄的影响.

研究的目的:

为了评估捐赠者年龄对HCT结果的影响,使用以PTCy为基础的GVHD预防的哈普罗同一性或MMUD捐赠者.
为了比较年轻 (<30岁) 和老 (≥30岁) 捐赠者之间的结果,分别在 haploidentical 和 MMUD 类别中.

主要方法:

来自国际血液和骨髓移植研究中心数据库 (2013-2021) 的7116名HCT患者的回顾性分析.
捐赠者被分为:年轻的平分标识性,年长的平分标识性,年轻的MMUD和年长的MMUD.
主要结局:无GVHD的无复发生存期 (GRFS). 二级结局:整体存活率,TRM,复发和GVHD发生率.

主要成果:

较年长的MMUD捐赠者与较年轻的平分异性捐赠者相比,具有较差的GRFS,较高的TRM,以及III-IV级急性GVHD的增加.
较年轻的MMUD捐赠者与较年长的平分标识性捐赠者相比,显示了适度的GRFS改善和急性和慢性GVHD风险降低.
较年轻的供体年龄 (<30岁) 与各类供体中优异的HCT结果有关.

结论:

较年轻的捐赠者年龄 (<30岁) 是与改善的HCT结果相关的重要因素,包括GRFS,TRM和GVHD发病率.
在可行的情况下,建议优先考虑年轻的捐赠者 (<30岁),无论他们是否是 haploidentical 或 MMUD.
这些发现支持优化供体选择,以提高HCT的成功率.

关键词:

供体年龄供体年龄发生了完全相同的事件.MMUD MMUD 在线播放不匹配的无血缘关系的捐赠者在 PTCy 中.移植后的循环胺基.

更多相关视频

A Modified Murine Heterotopic Heart Transplant Protocol Matching Contemporary Standards of Aseptic Technique, Anesthesia, and Analgesia

A Modified Murine Heterotopic Heart Transplant Protocol Matching Contemporary Standards of Aseptic Technique, Anesthesia, and Analgesia

Published on: September 28, 2022

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...